SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

The TIMI Risk Score for Atherothrombosis in Diabetes categorises risk of myocardial infarction or stroke in people with type 2 diabetes.

The results of ONWARDS 2 show significantly improved glycemic control with weekly insulin icodec versus daily insulin degludec, without significantly increased hypoglycemia, in people with type 2 diabetes.

An algorithm based on real-world clinical data could support decisions between use of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes.

Two linked randomized trials published in JAMA support a role for verapamil, but not for intensive glycemic control, to slow C-peptide decline in children with newly diagnosed type 1 diabetes.

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

Clinical complexity and treatment burden have both increased over recent years among people with diabetes in the USA, say researchers.

Combination therapy with three commonly used medications has achieved similar levels of pain relief for people with diabetic peripheral neuropathic pain in the randomized OPTION-DM trial.

A number of factors are associated with severe hypoglycemia risk in people with type 2 diabetes treated with insulin or sulfonylureas, suggests research reported at the 58th EASD Annual Meeting in Stockholm, Sweden.

The temporal analysis of UK clinical practice data showed that metformin is still the most commonly prescribed medication among people with type 2 diabetes, with or without CKD, but its use has declined since 2006, with other drug classes becoming more common.

Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature.

People with type 2 diabetes develop other chronic conditions more frequently and around 5 years earlier than those without, say researchers.

Poor glycemic control is associated with an impaired immune response to vaccination against SARS-CoV-2 and an increased risk for breakthrough infections in people with type 2 diabetes, report researchers.

Only a third of people given a glucagon-like peptide-1 receptor agonist in clinical practice lose a clinically meaningful amount of weight, potentially due to high rates of discontinuation, say researchers.